David Domenichini, MD
Endocrinology, Diabetes & Metabolism · Bloomfield, CTNPI 1225004922
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $181,532 of the $220,302 with a category attached, or 82.4%. 59 manufacturers reported payments, led by Novo Nordisk at 55.6% of the total. Reporting peaked in 2019 at $57,995 and has fallen 69.5% since, to $17,713 in 2025. Among endocrinology, diabetes & metabolism clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,152 payments — averaging $191.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$122K
- Dexcom, Inc.$46K
- AstraZeneca$14K
- AbbVie$8K
- Johnson & Johnson$7K
- Merck$7K
- plus $17K from 53 others
What the payments were for
- Consulting fees$2,2501%
- Speaking & faculty fees$181,53282%
- Travel & lodging$11,8975%
- Food & beverage$24,14711%
- Education$4170%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$45,915
- Ozempic$45,860
- DEXCOM G7 GSS (161)$26,232
- Tresiba$15,991
- FARXIGA$13,097
- DEXCOM G6 TRANSMITTER$10,762
- Synthroid$7,323
- INVOKANA$6,358
- STEGLATRO$6,189
- DEXCOM G6 CGM SYSTEM$4,895
- Korlym$3,286
- DEXCOM CGM$2,480
- Xultophy 100/3.6$2,363
- V-GO$750
- TOUJEO$734
- Kerendia$656
- TEPEZZA$303
- NURTEC ODT$237
- Prolia$227
- LEQVIO$140
How this compares
$220,302 in reported general payments places this provider in the 95th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 866 | $1,385,100 |
| JardianceEmpagliflozin | 383 | $588,155 |
| Tresiba Flextouch U-200Insulin Degludec | 249 | $424,628 |
| TrulicityDulaglutide | 238 | $367,847 |
| FarxigaDapagliflozin Propanediol | 180 | $251,660 |
| MounjaroTirzepatide | 201 | $234,321 |
| JanumetSitagliptin Phos/Metformin Hcl | 182 | $233,512 |
| Tresiba Flextouch U-100Insulin Degludec | 218 | $175,426 |
| JanuviaSitagliptin Phosphate | 113 | $167,204 |
| ProliaDenosumab | 60 | $104,980 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $94,571 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 91 | $81,977 |
| SynthroidLevothyroxine Sodium | 606 | $73,443 |
| TradjentaLinagliptin | 57 | $67,560 |
| Humalog Kwikpen U-100Insulin Lispro | 166 | $62,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $122,436 | $1,393,003878 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $713 | $668,289453 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,419 | $613,645477 claims |
| MerckJanumet, Januvia, Janumet Xr | $6,596 | $437,372321 claims |
| AstraZenecaFarxiga | $13,784 | $251,660180 claims |
| AmgenProlia | $1,559 | $104,98060 claims |
| AbbVieSynthroid | $8,154 | $73,443606 claims |
| Johnson & JohnsonInvokana | $6,699 | $23,23314 claims |
| PfizerGenotropin | $73 | $11,17913 claims |
| Antares Pharma, Inc.Xyosted | $367 | $11,02214 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $319 | $7,878788 claims |
| Sanofi-aventis U.S. LLCLantus | $1,456 | $5,64419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Bloomfield
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Joseph RosenblattNew Britain$235K
- Glenn RichTrumbull$210K
- Gerald ShulmanNew Haven$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.